Policy to position the medical business as a future growth area
First written in FY2016. 18 of 23 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「As a result, total revenue from the Medical business was ¥24,936 million, up 1.4% year on year.」
For the Medical business, positioned as a growth area, revenue rose 1.4% year on year. However, segment profit fell 4.4% year on year due to lower sales of high-gross-margin products. - FY2025-H1AdvancedAnnual report
「As a result, total revenue from the Medical business was ¥11,807 million, up 8.6% year on year. … Segment profit was ¥3,120 million, up 7.8% year on year.」
For the Medical business, positioned as a growth area, both revenue and segment profit exceeded the year-earlier period. - FY2024-Q3AdvancedAnnual report
「As a result, total revenue from the Medical business was ¥17,446 million, up 11.0% year on year. Despite higher raw material unit prices, segment profit rose 37.8% year on year to ¥4,998 million due to a substantial increase in production and higher revenue, mainly from Healthcare Field products.」
For the Medical business, positioned as a growth area, revenue rose 11.0% year on year and segment profit rose 37.8%, indicating growth in both business scale and profit. - FY2024-Q2RestatedAnnual report
「As a result, total revenue from the Medical business was ¥10,843 million, up 12.9% year on year. Despite higher raw material unit prices, segment profit rose 51.2% year on year to ¥2,975 million due to a substantial increase in production and higher revenue, mainly from Healthcare Field products.」
The company continues to position its Medical business as a growth area and reports increases in revenue and segment profit. - FY2024-Q1RestatedAnnual report
「As a result, total revenue from the Medical business was ¥5,330 million, up 13.7% year on year.」
The company continues to position its Medical business as a growth area, with total business revenue rising 13.7% year on year due to expanding demand for Healthcare Field products and other offerings. - FY2023-Q2RestatedAnnual report
「As a result, total revenue from the Medical business was ¥9,606 million, up 4.6% year on year.」
The company continues to operate its Medical business as a growth area and reports that total business revenue rose 4.6% year on year. - FY2023-Q1RestatedAnnual report
「As a result, total revenue from the Medical business was ¥4,544 million, up 2.2% year on year. Although production plant utilization for the Medical business increased with higher revenue, operating profit fell 11.2% year on year to ¥979 million due to higher raw material unit prices, including the rise in naphtha prices, and higher costs resulting from increased electricity and fuel expenses, among other factors.」
The company continues to position its Medical business as a growth area. Revenue rose 2.2% year on year, while operating profit fell 11.2% due to higher raw material and energy costs. - FY2022RestatedAnnual report
「As sales increased, cost improvements resulting mainly from the significant recovery in operating rates at production plants related to the medical business」
The company continues to operate its Medical business as a growth area, citing the recovery in plant utilization and cost improvements as growth drivers. - FY2022-Q3RestatedAnnual report
「As sales increased, cost improvements resulting mainly from the significant recovery in operating rates at production plants related to the medical business」
The company continues to operate its Medical business as a growth area, citing the recovery in production plant utilization and cost improvements as growth drivers. - FY2022-Q2RestatedAnnual report
「As sales increased, cost improvements resulting mainly from the significant recovery in operating rates at production plants related to the medical business brought the figure to ¥1.222 billion, compared with ¥877 million in the same period of the previous year.」
The policy of operating the medical business as a growth area continues, with the company reporting a recovery in production plant operating rates, cost improvements, and an increase in operating profit. - FY2021-Q1RestatedAnnual report
「As a result, total medical business sales, including the overseas business and combining the healthcare and medical materials fields, amounted to ¥3.778 billion, down 24.5% year on year, while operating profit amounted to ¥799 million, down 40.4%.」
The medical business continues to be operated as a growth area, but sales and operating profit fell below the same period of the previous year due to declines in inbound and sports demand and decreases in patient numbers and surgical procedures at medical institutions resulting from the spread of COVID-19. - FY2020-Q3RestatedAnnual report
「As a result, total medical business sales, including the overseas business and combining the healthcare and medical materials fields, amounted to ¥15.462 billion, down 5.5% year on year, while operating profit amounted to ¥3.991 billion, down 7.4%.」
The medical business continues to operate, but sales and operating profit both fell below the same period of the previous year for the nine-month cumulative period. No change in the policy of positioning it as a growth area has been stated. - FY2020-Q2RestatedAnnual report
「As a result, total medical business sales, including the overseas business and combining the healthcare and medical materials fields, amounted to ¥10.411 billion, down 3.7% year on year, while operating profit amounted to ¥2.776 billion, down 3.6%.」
The medical business continues to operate, but sales and operating profit fell below the same period of the previous year during the quarter, due in part to a slowdown in inbound demand. No change in the policy of positioning it as a growth area has been stated. - FY2020-Q1RestatedAnnual report
「As a result, total medical business sales, including the overseas business and combining the healthcare and medical materials fields, amounted to ¥5.008 billion, down 6.6% year on year, while operating profit amounted to ¥1.341 billion, down 9.7%.」
The medical business continues to operate, but sales and operating profit fell below the same period of the previous year during the quarter, due in part to a slowdown in inbound demand. - FY2019AdvancedAnnual report
「To meet growing demand for analgesic and anti-inflammatory products and prescription patches, we are expanding production at the Medical Anjo Plant, completed in January 2018, and will continue delivering products of more reliable quality.」
Based on the policy of positioning the medical business as a growth area, the company has progressed to the stage of expanding production at the completed Medical Anjo Plant. - FY2019-Q3RestatedAnnual report
「As a result, sales increased 1.8% year on year to ¥35.704 billion, driven by the expansion of the medical business.」
The expansion of the medical business continues to be identified as a factor behind the increase in consolidated sales. - FY2019-Q2RestatedAnnual report
「As a result, sales increased 3.9% year on year to ¥23.316 billion, driven by the expansion of the medical business.」
The medical business continues to be positioned as a growth area, with its expansion identified as a factor behind the increase in consolidated sales. - FY2019-Q1RestatedAnnual report
「As a result, sales increased 5.4% year on year to ¥11.328 billion, driven by expanded medical business sales.」
Expanded medical business sales continue to be identified as a growth driver, with sales growth reported for the quarter. - FY2018-Q2RestatedAnnual report
「As a result, total medical business sales, including the overseas business and combining the healthcare and medical materials fields, amounted to ¥10.043 billion, up 9.3% year on year, while operating profit amounted to ¥3.159 billion, up 29.2%.」
The medical business continues to be positioned as a growth area, with increases in sales and operating profit reported for the cumulative period. - FY2017RestatedAnnual report
「As a result of these initiatives, total medical business sales, combining the healthcare and medical materials fields, increased 11.0% from the previous consolidated fiscal year to ¥18.5 billion, while operating profit increased 20.4% to ¥5.208 billion.」
The medical business continues to be positioned as a growth area, with increases in sales and operating profit reported. - FY2017-Q3RestatedAnnual report
「We have changed the planned investment amount from ¥6.0 billion to ¥8.0 billion to establish future production capacity in response to strong performance of medical business products.」
Based on the continued positioning of the medical business as a growth area, the company describes strong product performance and the establishment of future production capacity. - FY2017-Q2RestatedAnnual report
「We have changed the planned investment amount from ¥6.0 billion to ¥8.0 billion to establish future production capacity in response to strong performance of medical business products.」
Based on the continued positioning of the medical business as a growth area, the company describes strong product performance and the establishment of future production capacity. - FY2016First statedAnnual report
「We are proceeding with plans to build a new plant in Anjo, Aichi Prefecture, to expand production capacity in response to growing demand for OTC and prescription patches in the medical business, which we have positioned as a future growth area.」
The medical business is positioned as a growth area, with demand expected to increase.